by rss feed | Mar 4, 2026 | journal club, laromestrocel, Longeveron, mesenchymal cells, MSCs frailty, News Feeds
Longeveron is a biotech studying clinical applications of mesenchymal stromal/stem cells or MSCs . MSCs are interesting, usually heterogeneous cell preparations. They are probably most well known for modulating the behavior of other cells via their secretome. The...
by rss feed | Jul 18, 2025 | 3-parent IVF, journal club, mitochondrial disease, mitochondrial donation, News Feeds, pronuclear transfer
A new reproductive method called mitochondrial donation has reached a milestone. The goal of this approach is to prevent mitochondrial diseases in children whose mothers have disease-associated mitochondrial DNA. Two linked NEJM papers on report encouraging results in...
by rss feed | Jun 11, 2025 | anti-aging, journal club, News Feeds, rejuvenation gene, SB000, Shift Bioscience
What if there was a rejuvenation gene that made adult cells younger without turning them into potentially destructive embryonic, fetal, or tumor cells? It could be transformative for how we think about cellular aging and have many impacts on health. A new preprint...
by rss feed | Jun 11, 2024 | journal club, MSC-NPs, MSCs for MS, Multiple Sclerosis, News Feeds, Tisch MS Research Center
The idea of mesenchymal cells or MSCs for MS has been around for a long time. However, there haven’t been that many strong clinical trials testing it. There’s a new paper out that reports one of the stronger MSC-related trials for MS in terms of design. In...
by rss feed | Apr 10, 2024 | journal club, News Feeds, stem cells for paralysis
A new paper on stem cells for paralysis from a Mayo Clinic team has sparked a bit of legitimate hope but also some hype in the media. The publication was in Nature Communications. It is entitled “Intrathecal delivery of adipose-derived mesenchymal stem cells in...
by rss feed | Mar 12, 2024 | Fact-check, journal club, News Feeds, RGCC, SOT therapy, supportive oligonucleotide therapy
A few dozen clinics in the US sell an unproven RNA therapy called supportive oligonucleotide therapy or SOT. The product comes from a Greek firm RGCC or Research Genetic Cancer Center, which also pre-tests patients’ gene expression to design the RNA product....
